Bioprocess Engineer / Scientist 2 - R&D Strategic Innovation Accelerator
About the job
- Bachelor’s or Master’s degree in Chemical Engineering, Bioengineering, Bioprocess Engineering, or a related field
- 2–4 years of relevant hands-on experience in downstream processing, protein purification, or bioprocess development
- Experience with downstream unit operations such as chromatography, filtration, harvest clarification, or ultrafiltration/diafiltration
- Experience designing chromatography experiments and operating ÄKTA systems is preferred
- Strong engineering fundamentals as applied to bioseparations unit operations
- Strong quantitative problem-solving, data-analysis, and experimental-design skills
- Mechanical aptitude for troubleshooting and maintaining laboratory equipment
- Experience with mammalian cell culture, bioreactors, automation, programming, or assay development is a plus
- Design and execute laboratory-scale downstream processing experiments involving chromatography, filtration, harvest clarification, and ultrafiltration/diafiltration
- Operate, maintain, and troubleshoot bioprocessing equipment and associated control systems
- Develop scalable, high-throughput, or automated experimental workflows that generate high-quality, reproducible process data
- Apply engineering principles to evaluate process performance, solve practical problems, and guide iterative experimental design
- Contribute flexibly across adjacent technical areas, including cell culture, bioreactor operation, automation, and analytical assays
- Communicate results clearly and contribute effectively within fast-paced, multidisciplinary teams
About the company
Lonza is a global provider of development and manufacturing services for the pharmaceutical, biotechnology, and nutrition sectors. It supports clients from early development through to commercial production, offering integrated processes such as process development, GMP manufacturing, formulation, fill-finish, and quality assurance to bring medicines and nutrition products to market. Lonza’s model is built on end-to-end CDMO capabilities, enabling companies to move from concept to scalable, compliant production with reliable supply chains. What sets Lonza apart is its long history and global footprint, combining decades of experience across chemistry, biology, and nutrition with a broad, end-to-end service network that supports projects from discovery to commercialization. The company aims to be a trusted, long-term partner in life sciences by helping customers efficiently develop and manufacture their products at scale while maintaining strict regulatory and quality standards.
Company Size
10,001+
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1897
Get referred to Lonza
See people who can refer or advise you
Simplify's Take
What believers are saying
- H1 2026 sales reached CHF 3.4 billion; CORE EBITDA margin hit 34.8%.
- Lonza launched RaMP on 17 August 2026, cutting media prototyping to 10 days.
- September 2026 Bend groundbreaking adds 80+ jobs and broadens U.S. customer proximity.
What critics are saying
- Lonza's 2026 pure-play shift depends on CHI closing and integration by year-end.
- Natals litigation in October 2026 exposes discovery failures and damages credibility.
- If 2029 Bend capacity underfills, Lonza becomes a capital-heavy, weaker-diversified CDMO.
What makes Lonza unique
- Lonza's March 2026 CHI divestiture makes it a pure-play CDMO.
- Bend, Oregon, gives Lonza rare U.S. commercial spray-drying capacity by 2029.
- Asimov partnership adds in vivo lentiviral-vector manufacturing with AI-native cell-line design.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
17%1 year growth
17%2 year growth
17%Lonza expands dual-payload ADC technology offering through exclusive access to Qurient's CDK7 inhibitors. Lonza Group AG / key word(s): agreement Lonza expands dual-payload ADC technology offering through exclusive access to Qurient's CDK7 inhibitors 12.10.2026 / 14:00 CET/CEST. * The dual-payload platform agreement adds CDK7 inhibitor technology to Lonza's technology toolbox for dual-payload ADCs, which can be combined with any other counterpart payloads using Lonza's technology. * The initial dual-payload discovered and launched under this collaboration is known as SYN-duo(R) CC, which represents a combination of exatecan and Qurient's CDK7 inhibitor and provides a new, off-the-shelf linker-payload for dual-payload ADC design and development. * The agreement exemplifies Lonza's strategy to expand its offering of cutting edge, proprietary technologies and further strengthen its position in the growing ADC market. Basel, Switzerland and Seongnam, Korea, 12 October 2026 - Lonza, the world's leading contract development and manufacturing organization (CDMO), and Qurient Co. Ltd., a clinical-stage biopharmaceutical company, announced today an exclusive license agreement for the use of Qurient's cyclin-dependent kinase 7 (CDK7) inhibitors for dual-payload antibody-drug conjugate (ADC) applications. Dual-payload ADCs carry two different cytotoxic payloads on a single antibody, allowing them to attack each tumor cell through multiple mechanisms at the same time. The agreement includes Qurient's highly selective and potent clinical stage CDK7 inhibitor designed to target multiple hallmarks of cancer. Christian Seufert, Head of Advanced Synthesis, Lonza, commented: "Dual-payload ADCs are among the most promising areas of innovation for customers developing differentiated cancer therapies. This agreement adds a differentiated CDK7 inhibitor payload technology to Lonza's ADC toolbox and further strengthens our ability to support customers from early technology evaluation through development, manufacturing and commercialization. With SYN-duo(R) CC and customizable dual-payload formats, we can offer customers more choice and flexibility as they design and advance the next-generation of ADC programs." Kiyean Nam, CEO, Qurient, added: "We believe CDK7 inhibition offers significant potential as part of the next generation of dual-payload ADCs. This agreement expands the opportunity to apply our CDK7 inhibitors across a broader range of ADC programs by combining Qurient's CDK7 expertise with Lonza's established ADC technology and development capabilities. We look forward to seeing SYN-duo(R) CC and future customized formats support the exploration of new approaches for patients with unmet medical needs." Through the agreement, Lonza will expand its ADC technology offering with SYN-duo(R) CC, a new dual-payload that combines a topoisomerase 1 inhibitor, a camptothecin derivative and a specific CDK7 inhibitor. The novel format is intended to provide ADC developers with an additional option for designing dual-payload ADCs where the CDK7 inhibitor potentiates the activity of the topoisomerase 1 inhibitor within a single targeted therapeutic approach. Beyond the combination of exatecan and Qurient's CDK7 inhibitor contained within SYN-duo(R) CC, under this agreement Lonza can leverage its existing proprietary platform to derive additional, novel combinations of Qurient's CDK7 inhibitor with any other payload in the dual-payload ADC setting. The agreement supports Lonza's strategy to expand proprietary technologies that complement its integrated CDMO services. By adding access to Qurient's CDK7 inhibitors for dual-payload ADC applications, Lonza is broadening its technology offering in ADCs, a strategically important modality where customers are seeking more flexible approaches to molecule design, development and manufacturing. About Lonza Lonza is the world's leading contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry. Working across five continents, Lonza's global team of approximately 20,000 colleagues works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. This enables customers to bring life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing. Its company generated sales of CHF 3.4 billion with a CORE EBITDA of CHF 1.2 billion in Half-Year 2026. Find out more at www.lonza.com. Lonza Contact Details Daniel Buchta Head of Investor Relations Lonza Group Ltd Tel +41 61 316 2985 [email protected] Victoria Morgan Head of External Communications Lonza Group Ltd Tel +41 61 316 2283 [email protected] Additional Information and Disclaimer Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release. All trademarks belong to Lonza, and are registered in the USA, EU and/or CH, or used in common law, or belong to their respective third-party owners and are used for informational purposes only. End of Media Release View original content: EQS News | Language: | English | | Company: | Lonza Group AG | | / | Münchensteinerstrasse 38 | | / | 4052 Basel | | / | Switzerland | | Phone: | +4161 316 81 11 | | Internet: | www.lonza.com | | ISIN: | CH0013841017 | | Valor: | 1384101 | | Listed: | SIX Swiss Exchange | | EQS News ID: | 2413778 | | End of News | EQS News Service | 2413778 12.10.2026 CET/CEST The discussion is visible to sharewise members.
Lonza, Onava strike AI biologics pact to speed drug discovery. Swiss manufacturing giant aims to help biotech turn AI-generated drug designs into development-ready candidates faster October 9, 2026 Associate Editor, Contract Pharma Editor's Take: AI can design drug candidates in days, but validating those designs in the lab remains a costly and time-consuming hurdle. Lonza and Onava are betting that tighter integration between AI models and experimental data generation will help produce biologic therapies that are not only effective but also easier to manufacture at commercial scale. Lonza has entered a collaboration with biotechnology startup Onava aimed at accelerating the development of AI-designed biologic drugs, underscoring a broader industry push to bridge the gap between artificial intelligence and real-world laboratory validation. Under a research evaluation, Onava will use Lonza's GS Gene Expression System and GS Ori-Go vectors to test and refine biologic drug candidates generated by its AI-native discovery platform. The companies said the arrangement is designed to shorten the path from computational predictions to experimental evidence, a key bottleneck in AI-driven drug development. Rather than relying solely on computer-generated predictions, Onava plans to feed experimental results from Lonza's expression system back into its platform, creating a continuous feedback loop intended to improve future drug designs. For Onava, the agreement provides access to industry-standard expression technology that can generate large-scale datasets on how AI-designed molecules perform in biological systems. The company said those insights will help it optimize not only for therapeutic activity but also for manufacturability and development readiness, factors that often determine whether a drug candidate can successfully advance toward commercialization. The companies indicated the collaboration could extend beyond an initial program. Onava expects to use Lonza's technology across multiple external partnerships as well as selected internal research efforts. The partnership also positions Lonza to capture downstream development and manufacturing work if candidates emerging from the collaboration advance into later-stage development. The announcement comes as pharmaceutical and biotechnology companies increasingly combine AI-driven discovery tools with established laboratory platforms in an effort to reduce development timelines, improve candidate selection and lower the risk of failure in later stages of drug development. Add us as a preferred source on Google. Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.
Lonza and Asimov join forces on In Vivo lentiviral vector manufacturing. 2 October 2026 Leading Swiss contract development and manufacturing organization (CDMO) Lonza (SWX: LONN) and Asimov, which is building an AI-native synthetic biology platform to advance therapeutic development, today announced a strategic collaboration to advance lentiviral vector (LVV) manufacturing for emerging in vivo applications. The collaboration brings together Asimov's LV Edge system cell line technologies with Lonza's expertise in process development, scale-up, analytics and GMP manufacturing. By connecting early design decisions with development and manufacturing considerations, the collaboration helps developers incorporate manufacturing considerations earlier in development, creating a stronger foundation for scalable clinical and commercial production. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 14 September 2026 22 July 2026 21 July 2026 Company news directory. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 2 October 2026 Company spotlight. A privately held US radiopharma company that produces actinium-225 and copper-67 on electron accelerators in Beloit, Wisconsin, and makes finished radiopharmaceutical doses for more than 30 drug developers. More features in biotechnology. 2 October 2026
Lonza Capsugel launches integrated offering supporting drug product nitrosamine risk management. New service combines sensitive nitrite testing, capsule and formulation expertise, and regulatory support to help manufacturers navigate increasingly complex nitrosamine assessments. BASEL, Switzerland, September 24, 2026 - Lonza Capsugel, a global leader in oral dosage solutions, today announced a new integrated service offering designed to help pharmaceutical manufacturers assess and understand nitrite levels in empty capsules through nitrite testing supported by a validated analytical method, scientific interpretation and regulatory support from a single trusted partner. As nitrites in empty capsules may contribute to nitrosamine formation in the drug product, scientific expertise and reliable nitrite testing data are required to perform a product-specific evaluation and support informed risk management decisions. Lonza Capsugel's integrated service enables customers to generate reliable evidence and define an appropriate nitrite risk-management approach aligned with their product needs. Services include nitrite testing, data interpretation, documentation to support regulatory submissions, scientific consultation, risk investigations, collaborative studies that facilitate engaging with regulators, all through a single point of contact for testing and technical support. At the core of the offering is Lonza Capsugel's fit-for-purpose nitrite quantification method specifically developed for the gelatin capsule matrix. The method combines ion chromatography with Griess derivatization, has been extensively validated in accordance with ICH Q2(R2) principles and can quantify nitrite levels as low as 100 ppb. By addressing matrix-specific extraction, selectivity and potential interferences, the method delivers sensitive and reliable nitrite quantification. The analytical capability supports capsule and comparative nitrite testing and customer-specific investigations. "As the industry's understanding of nitrosamine risk continues to evolve, manufacturers are moving beyond broad risk assessments toward more product-specific decision-making," said Bart Pelgrims, Vice President, R&D, Lonza Capsugel. "That shift requires not only reliable analytical data, but also the ability to interpret that data in the context of drug formulation, manufacturing processes and regulatory requirements. By bringing these capabilities together, we help customers develop risk management strategies that are both scientifically robust and practical to implement at scale." Regulatory authorities worldwide require marketing authorization holders to assess and mitigate potential nitrosamine risks. Acceptable daily intake limits for individual nitrosamine impurities are translated into product-specific concentration limits for patient safety. These measures may include nitrite concentration limits on excipients depending on the product composition. The new offering expands Lonza Capsugel's portfolio of scientific and technical services, providing manufacturers with a comprehensive approach to nitrite evaluation and support for product-specific nitrosamine assessments. Lonza Capsugel Media Contacts: Anne Holderbach Director, Strategic Marketing Lonza Capsugel Tel +33 76 267 9876 Deb Oliveri Senior Manager, External Communications Lonza Capsugel Tel +1 551-370-4127 Disclaimer Certain matters discussed in this press release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this press release. All trademarks belong to Lonza Group Ltd and are registered in CH, US and/or EU, or belong to their respective third-party owners and are used only for informational purposes. Downloads.
Lonza breaks ground on $235 million Bend expansion with more than 700 jobs expected. BEND, Ore. - An expanded biotech manufacturing facility in Bend will create more than 80 high-wage permanent jobs and 650 construction jobs. In a Sept. 14 press release, Governor Tina Kotek announced the start of the project, which she says will strengthen regional economic growth and bolster Oregon's growing life sciences and advanced manufacturing industries. The project expands existing facilities in Bend owned by Swiss-based Lonza, a Contract Development and Manufacturing Organization (CDMO). Using advanced particle engineering and spray drying technologies, Lonza's Bend operation has supported the evaluation or development of more than 2,000 potential medicines. The new facility is earmarked for completion by 2029. The City of Bend is the first Oregon local government to use the expanded incentives offered by Governor Kotek's House Bill 4084, passed by legislators earlier this year as part of her Prosperity Roadmap. Tidings Data Snapshot How Bend's Expanded Tax Incentive Works | Feature | Program | | Standard exemption | 3 to 5 years | | Expanded option | Up to 10 years | | What qualifies | Qualified new investment | | Existing property | Remains taxable | Sources: City of Bend and Business Oregon / 2026 Dailytidings.com Oregon leads the life sciences sector. Oregon is a national leader in the life sciences sector and is home to firms such as Genentech, Lonza, and Thermo Fisher. Tidings Data Snapshot Oregon Bioscience Employment Growth Growth from 2002 to 2023 Research and testing labs: +226% Life science research: +176% Private bioscience overall: +127% Medical devices: +66% This sector generated $21.2 billion for the economy in 2023, supported nearly 75,000 jobs and 2,500 businesses statewide, and contributed $5.6 billion in exports. The expansion to the Bend site represents a total capital investment of $235 million and will strengthen Lonza's presence in the U.S. Two state-of-the-art spray drying units will be installed at the new facility, enabling Lonza to offer a full range of spray-dried dispersion (SDD) capacity to support both clinical and commercial customers. In a statement, Lonza says its world-class particle engineering team based in Bend will support customers by transforming breakthrough innovations into viable products and enabling the manufacture of medicines of the future. By Lucille McNamara | Covers public safety, courts and Oregon policy